OxyContin OC 20mg – The Complete Medical Guide

OxyContin OC 20mg is an extended-release oxycodone formulation classified as a Schedule II controlled substance. This intermediate-strength tablet is designed for around-the-clock management of moderate to severe chronic pain in opioid-tolerant patients. The “OC” designation refers to the original formulation (prior to 2010) which lacked modern abuse-deterrent properties, making it particularly high-risk for misuse.

Oxycontin OC 20mg

OxyContin OC 2 mg is a prescription medication containing oxycodone, an opioid used to manage moderate to severe chronic pain. The “OC” formulation refers to the original controlled-release version, which provides long-lasting, consistent pain relief by releasing oxycodone slowly over time.

OxyContin OC 20mg is typically prescribed for patients with persistent pain who require around-the-clock management. Due to its potential for misuse and serious side effects, it is essential to use this medication under the supervision of a healthcare provider.

Key Benefits:

• Provides extended, controlled-release pain relief
• Effective for managing moderate to severe chronic pain
• Ideal for 12-hour pain management

Important Considerations:

• Risk of dependence, overdose, and misuse
• Common side effects include constipation, drowsiness, and dizziness
• Avoid alcohol and other sedatives while using OxyContin

Always consult with your doctor to determine if OxyContin OC 20 mg is appropriate for your pain management needs.

Medical Uses & Indications

FDA-Approved Uses

 Moderate to severe chronic pain requiring continuous opioid therapy
 Cancer pain management in opioid-tolerant patients
 Pain uncontrolled by immediate-release opioids

Key Clinical Features

• Formulation: Original controlled-release (not abuse-deterrent)
• Onset: 1-2 hours
• Duration: 12-hour controlled release
• Equianalgesic ratio: 20mg q12h ≈ 30mg oral morphine daily
• DEA Classification: Schedule II (Highest abuse potential)

Pharmacology & Mechanism

Neurochemical Action

• Full μ-opioid receptor agonism
• κ-opioid receptor partial agonism
• Sustained activation of pain modulation pathways

Metabolic Profile

• Hepatic metabolism: CYP3A4 (major), CYP2D6 (minor)
• Active metabolites: Oxymorphone (via CYP2D6)
• Elimination half-life: 4.5-8 hours (ER formulation)

Dosing & Administration

Strict Eligibility Criteria

• Confirmed opioid tolerance: ≥30mg oral morphine equivalent daily
• Stable pain pattern (Not episodic/breakthrough)
• Failed trials of non-opioid alternatives

Conversion Protocol

1. Calculate total daily morphine equivalent

2. Reduce by 25-50% (incomplete cross-tolerance)

3. Divide by 2 for q12h dosing

Critical Safety Notes

 Never prescribe to opioid-naïve patients
 Original formulation lacks abuse-deterrent properties
 High risk if crushed/chewed (immediate 20mg release)
 Naloxone co-prescription mandatory

Safety Profile

Common Adverse Effects

• Constipation (universal, requires prophylaxis)
• Nausea/vomiting (30-40%)
• Sedation/dizziness
• Pruritus (20-25%)

Black Box Warnings

 High addiction/abuse potential (especially when manipulated)
 Life-threatening respiratory depression
 Accidental exposure danger
 Concomitant CNS depressant risk

Risk Mitigation Strategies

Prescribing Safeguards

1. Documented failed trials of abuse-deterrent formulations

2. Dual prescriber verification required

3. Weekly follow-ups for first 3 months

4. Random urine drug screening

Patient Monitoring

• Monthly prescription drug monitoring program (PDMP) checks
• Pill counts at each visit
• Assessment for aberrant behaviors

Clinical Alternatives

For Chronic Pain

• OxyContin OP (abuse-deterrent formulation)
• Xtampza ER (abuse-deterrent oxycodone)
• Methadone (For select patients)

Non-Opioid Options

• Duloxetine (For neuropathic pain)
• Gabapentin enacarbil
• Interventional pain procedures

Special Population Considerations